NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)
Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
Benzinga.com2d
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
FDA approves NovoCure's Optune Lua for metastatic non-small cell lung cancer after platinum-based regimen. Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months.
STAT3d
A controversial approval for Novocure’s device
From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical field medical device to include the treatment of metastatic non-small cell lung cancer.
Seeking Alpha2d
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...
FierceBiotech2d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first treatment ...
Yahoo Finance2d
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.